secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001104659-25-058525
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SOL-R enrollment complete; shareholders approve 8.75M share increase and CEO award
--------------------------------------------------------------------------------

- SOL-R Phase 3 trial for AXPAXLI (wet AMD) completed enrollment on May 31, 2025; target randomization of at least 555 subjects.
- Stockholders approved Amendment No. 4 increasing 2021 Stock Incentive Plan shares by 8,750,000 shares.
- Stockholders approved Amended and Restated ESPP increasing shares by 2,000,000 and removing evergreen provision.
- CEO Dr. Dugel granted performance stock option award for up to 2,750,000 shares at $7.44/share, vesting on stock price hurdles.
- Certificate of Amendment filed to provide officer exculpation (limitation of liability) per Delaware law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925058525/0001104659-25-058525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925058525/tm2517563d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-058525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer